Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

Advancing pipeline of inhaled treprostinil products in clinical studies Strengthened financial position by up to $100 million via amendment to existing financing agreement with HealthCare Royalty ...

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

Pulmonary Arterial Hypertension (PAH) is an often-overlooked yet life-altering disease that affects thousands globally, requiring lifelong management, rigorous monitoring, and substantial emotional ...

Under the terms of the Sixth Amendment, Liquidia will receive $25.0 million at closing with the potential to receive two additional tranches of funding: $50.0 million upon the first commercial sale of ...

Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

Data show people with pulmonary arterial hypertension tend to stay in the hospital longer and have higher medical bills.

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.

The drug’s developer, Cereno Scientific, believes its oral therapy could have a major impact on the pulmonary arterial ...

If you’re on medication for high blood pressure, they’ll likely ask if you’re taking your medication as prescribed and if you are checking your blood pressure at home. If so, your doctor ...

13 Several agents have been approved by the US Food and Drug Administration (FDA) for PAH, with various delivery methods, including oral, intravenous, subcutaneous, and inhaled (Table 3). 15,16 “In ...

Background Pulmonary hypertension (PHT) lacks community prevalence and outcome data. Objective To characterise minimum ‘indicative’ prevalences and mortality data for all forms of PHT in a selected ...